Vancouver, British Columbia--(Newsfile Corp. - June 17, 2025) - Omega Pacific Resources Ltd. (CSE: OMGA) ("Omega Pacific" or the "Company") is pleased to announce a non-brokered private placement financing of up to $1,975,000 (the "Offering") to support its 2025 exploration initiatives at the Williams Property, located in the very active Toodoggone District in northern British Columbia, Canada.Offering TermsThe Offering will consists of a combination of flow-through units (the "FT Units") and non flow-thro ...

Vancouver, British Columbia--(Newsfile Corp. - June 4, 2025) - Omega Pacific Resources Ltd. (CSE: OMGA) ("Omega Pacific" or the "Company") is pleased to announce its 2025 exploration strategy for the Williams Property, located in British Columbia's Toodoggone District. The Toodoggone is re-emerging as an important gold and copper-gold district, where several exciting mineral discoveries have recently been made, including Omega Pacific's 2024 gold discovery. In 2025, the District is experiencing a surge of ...

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.45%. A quarter ago, it was expected that this company would post a loss of $0.36 per share when it actually produced a loss of $0.30, delivering a surprise of 16.67%.Over the last four quarters, the company has ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------ ...

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will share new preclinical data at three upcoming scientific meetings. "These preclinical results build upon the foundation of data we have shared to date and expand our confidence in the ability of epigenomic controllers to upregulate or downregulate the expression ...

Treatment with OTX-2002 led to controlled downregulation of MYC gene expression and resulted in significant inhibition of tumor growth as a monotherapy and in combination with standard of care agents in preclinical models of HCC Proof-of-concept data for OTX-2002 support potential of epigenomic controllers to effectively target and modulate expression of nearly any human gene, including historically undruggable targets Data further validate the OMEGA platform's potential to rapidly and prospectively design, ...

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this company would post a loss of $0.38 per share when it actually produced a loss of $0.36, delivering a surprise of 5.26%. Over the last four quarters, the company ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |-------------------------------------------------------------------------------------------------------------|------------------------------------------| | | | | For the transit ...

Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress • Advanced MYCHELANGELO™ I trial; Company expects to select recommended dose for expansion and initiate monotherapy and combination expansion cohorts in fourth quarter of 2024 • Reinforced diverse capabilities of the OMEGA platform at scientific meetings, including demonstration of precise and durable upregulation of gene expression • Strengthened leadership team with appointment of Kaan Certel, Ph.D., as ...

Advanced MYCHELANGELO™ I trial; Company expects to select recommended dose for expansion and initiate monotherapy and combination expansion cohorts in fourth quarter of 2024 Reinforced diverse capabilities of the OMEGA platform at scientific meetings, including demonstration of precise and durable upregulation of gene expression Strengthened leadership team with appointment of Kaan Certel, Ph.D., as Chief Business Officer and election of Richard N. Kender to Board of Directors CAMBRIDGE, Mass., Aug. 06, 202 ...